newsfilter
← Latest News
GlobeNewswire·

MIRA Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain

  • MIRA Pharmaceuticals announced new pharmacological data for MIRA-55, an investigational oral drug for inflammatory pain, highlighting a differentiated profile with potent CB2 activation.
  • Receptor screening demonstrated approximately 680-fold separation from mu opioid receptors & 540-fold separation from kappa opioid receptors, with no substantial inhibition of COX-1 or COX-2.
  • The compound exhibits measurable CB1 activity alongside CB2 activation, targeting both peripheral inflammation & central nervous system pain processing pathways.
  • Preclinical studies confirmed MIRA-55's ability to penetrate brain tissue, offering potential influence on central pain-processing pathways in addition to peripheral effects.
  • Functional studies revealed distinct signaling effects, including inhibition of agonist-induced β-arrestin recruitment & limited antagonism of Gi/cAMP signaling, which may reduce psychiatric adverse risks.
  • Animal models showed anxiolytic-like effects & exploratory behaviors without significant THC-like motor impairment, distinguishing it from conventional cannabinoids.
  • In acute inflammatory pain models, oral MIRA-55 demonstrated greater pain relief than injected morphine, while chronic studies showed sustained relief comparable to celecoxib alongside reduced inflammation-associated swelling.
  • MIRA plans to advance MIRA-55 through IND-enabling activities with a target Investigational New Drug (IND) submission in the first half of 2027.
  • Ongoing preclinical evaluations include measurements of inflammatory cytokines to further characterize the drug's impact on inflammatory signaling.
  • The U.S. Drug Enforcement Administration has determined that MIRA-55, along with Ketamir-2 & SKNY-1, is not classified as a controlled substance.
Company
Mira Pharmaceuticals, Inc.
Keywords
Nasdaq:MIRA, Mira Pharmaceuticals, Inc., $MIRA, Mira Pharmaceuticals, MIRA-55, inflammatory pain, non-opioid pain treatment, CB2 receptor, selectivity findings, CB1 receptor